


## CB-7921220

<b>Cat. No.:</b>	HY-101862		
<b>CAS No.:</b>	115453-99-1		
<b>Molecular Formula:</b>	C <sub>14</sub> H <sub>12</sub> N <sub>2</sub> O <sub>2</sub>		
<b>Molecular Weight:</b>	240.26		
<b>Target:</b>	Adenylate Cyclase		
<b>Pathway:</b>	GPCR/G Protein		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 50 mg/mL (208.11 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	<b>Preparing Stock Solutions</b>	1 mM	4.1622 mL	20.8108 mL	41.6216 mL
		5 mM	0.8324 mL	4.1622 mL	8.3243 mL
10 mM		0.4162 mL	2.0811 mL	4.1622 mL	
Please refer to the solubility information to select the appropriate solvent.					
<b>In Vivo</b>	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (10.41 mM); Clear solution				

### BIOLOGICAL ACTIVITY

<b>Description</b>	CB-7921220 is an adenylate cyclase inhibitor.
<b>In Vitro</b>	CB-7921220 shows a degree of isoform selectivity for adenylate cyclase (AC) 1, but cannot distinguish between AC1 and AC6. CB-7921220 has a more consistent predicted binding position in the two virtual docking screens, and has a binding conformation similar to ATP and P-site inhibitors, which may explain its lack of selectivity between AC1 and AC6 <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Brand CS, et al. Isoform selectivity of adenylyl cyclase inhibitors: characterization of known and novel compounds. J Pharmacol Exp Ther. 2013 Nov;347(2):265-75.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA